Track Cybin Inc. Common Stock — Monitor price, dividends, and performance in your free portfolio

Start Tracking Free

Cybin Inc. Common Stock HELP · Stock Open Cybin Inc. Common Stock in new tab

6.24 USD
Add to portfolio
EPS
-4.30
P/B
115.25
ROE
-55.89
Beta
0.71
Target Price
42.75 USD
1M 6M YTD 1Y 2Y 5Y Max
Loading chart...
Key Metrics
Earnings dateAug. 6, 2026
EPS-4.30
Book Value0.05
Price to Book115.25
% Insiders3.716%
Estimates
Forward P/E-1.93
Forward EPS-3.11
Target Mean Price42.75

DCF Valuation

Tweak assumptions to recompute fair value for Cybin Inc. Common Stock (HELP)
Currency: USD
DCF Assumptions
Decimal (e.g., 0.10 = 10%). Range allows declines (−50%) to strong growth (+50%).
Decimal (e.g., 0.30 = 30%).
Decimal (e.g., 0.04 = 4%).
Decimal (e.g., 0.20 = 20%).
Percent number (e.g., 3 = 3%).
Percent number (e.g., 10 = 10%).
Percent number (e.g., 5 = 5%).
DCF Result
Fair Value (DCF)
—
Current Price
—
Upside
—
WACC
—
Terminal PV
—
Σ PV of FCFs
—
Note: historical bars show reported FCF (for context); forward bars show PV of projected FCF; if no per-year data, totals are shown.

Cybin Inc. Common Stock Logo Cybin Inc. Common Stock Analysis (HELP)

Canada Healthcare Official Website Stock

Is Cybin Inc. Common Stock a good investment? Cybin Inc. Common Stock (HELP) is currently trading at 6.24 USD. Market analysts have a consensus price target of 42.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Cybin Inc. Common Stock is expected to release its next earnings report on Aug. 6, 2026. The market consensus estimate for Forward EPS is -3.11.

Investor FAQ

Does Cybin Inc. Common Stock pay a dividend?

No, it does not currently pay a dividend.

What asset class is Cybin Inc. Common Stock?

Cybin Inc. Common Stock is classified as a Stock. You can compare it against 2 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be Aug. 6, 2026. The company currently has a trailing EPS of -4.30.

Company Profile

Cybin Inc., doing business as Helus Pharma, a clinical-stage neuropsychiatry company, focuses on developing psychedelic-based therapeutics for patients with mental health conditions. It develops CYB003, a deuterated psilocybin analog, which is in phase 3 clinical trial to treat major depressive disorder (MDD); and CYB004, a deuterated N, N-dimethyltryptamine (DMT), which is in phase 2 clinical trial for treating generalized anxiety disorders. The company also develops SPL028 injectable deuterated DMT completed phase 1 clinical intramuscular and intravenous trial; SPL026 for MDD; and CYB005, a phenethylamine derivative, which in preclinical stage to treat central nervous system, as well as has a research pipeline of investigational psychedelic-based compounds. It has a strategic partnership agreement with Segal Trials to support PARADIGM, a multinational pivotal phase 3 program evaluating CYB003 for the adjunctive treatment of major depressive disorder. The company is headquartered in Toronto, Canada.

Exchange Ticker
NASDAQ HELP
CYBN
Trades
Dividend History paid per year (USD)
No dividend history available.
Stock Splits
Split Date Split Ratio to 1
Nov. 10, 2020 0.149000
Sept. 19, 2024 0.026316
Explore Premium Features

Unlock detailed news and exclusive insights with our Premium subscription.

See Pricing Plans

Fundamentals

Under Construction

This feature will be available soon. Stay tuned!

Follow us on Twitter for updates: @allinvestview

Check out our Roadmap for upcoming features.

Community Discussion